Pedro Perez: Are We Measuring the Right Outcomes in VTE?
Pedro Perez, Senior Vascular Consultant at Argon Medical Devices, Inc., shared a post on LinkedIn:
”Are We Measuring the Right Outcomes in VTE?
In VTE, we often talk about technical success:
- Did we remove the clot?
- Did flow improve?
- Did the case go smoothly?
But the bigger question is… does that actually define success for the patient?
Because what matters long-term isn’t just what happens in the lab – it’s what happens after:
- Reduction in post-thrombotic syndrome
- Improvement in quality of life
- Decreased readmissions
- Shorter hospital stays and overall cost of care
As technology continues to evolve – from aspiration to more advanced thrombectomy approaches – we’re getting better at treating clot.
But as an industry, we need to continue shifting the conversation from procedural metrics to patient outcomes.
The next phase of VTE care won’t be defined by who has the newest device…
It will be defined by who can demonstrate meaningful, measurable impact on patients.”
Stay updated with Hemostasis Today.
-
Sep 17, 2026, 16:30Daria Camilli: Empowering Bleeding Disorder Advocacy Through Health Economics
-
Sep 17, 2026, 16:17Mehran Ghasemzadeh: Platelet NK Cell Crosstalk in Advanced Coronary Artery Disease
-
Sep 17, 2026, 16:16Barbara Adams Krolak: Do GLP-1s Affect Blood Clot Risk?
-
Sep 17, 2026, 15:46Heghine Khachatryan: Clinical Context at the Core of Thrombosis and Thrombophilia Management
-
Sep 17, 2026, 15:33Alexandros Makis: When Microcytic Anemia Has an Inherited Cause
-
Sep 17, 2026, 15:22α2-Antiplasmin Inhibition and the Future of Thrombolysis
-
Sep 17, 2026, 15:20Fatma M. Attia: Expanding the Evidence Base for Therapeutic Plasma Exchange Across Multiple Indications
-
Sep 17, 2026, 15:19Conan McIlwrath: The Haemophilia Society Engages With IBCA
-
Sep 17, 2026, 15:06Eleftheria Hatzimichael: A Contemporary Diagnostic Approach to Inherited Microcytic Anemias